Ribosome Structure and Function

A ribosome is a large ribonucleoprotein complex — part RNA, part protein — that translates the nucleotide sequence of mRNA into the amino acid sequence of a polypeptide. Every ribosome, in every domain of life, is built from two subunits of unequal size that associate only during active translation and can dissociate between rounds. The subunits are conventionally named by their sedimentation coefficient in Svedberg units (S), a measure of how fast a particle sediments in a centrifuge — a property that depends on both mass and shape, which is why S values do not simply add. In bacteria and archaea, the complete ribosome is a 70S particle assembled from a 30S small subunit and a 50S large subunit. In the eukaryotic cytosol, the complete ribosome is an 80S particle assembled from a 40S small subunit and a 60S large subunit. Mitochondria and chloroplasts carry their own distinct, smaller ribosomes reflecting their bacterial ancestry — a structural fossil of Endosymbiotic Theory. Each subunit is a composite of rRNA and ribosomal proteins, but the composite is lopsided: rRNA is the dominant mass and the geometric core, while proteins decorate the surface and fill in crevices between rRNA domains. The small subunit's job is decoding — checking that each incoming aminoacyl-tRNA's anticodon correctly pairs with the mRNA codon. The large subunit's job is catalysis — forming the peptide bond at the peptidyl transferase center (PTC) and threading the nascent chain into an exit tunnel. Both jobs converge at the subunit interface, where three tRNA-binding sites — A, P, and E — sit like adjacent parking spaces that a tRNA occupies in strict temporal order as it moves through the ribosome.

Subunit composition, piece by piece.

Despite the size difference, the mass ratio of RNA to protein is similar across domains: roughly 60% RNA, 40% protein by mass in bacteria, with eukaryotic ribosomes shifting somewhat toward more protein but keeping rRNA as the structural and catalytic backbone.

Small subunit: the decoding machine. The 16S/18S rRNA folds into a compact, elongated shape with a "head," "body," "platform," and "beak" — a nickname system from early cryo-EM/crystallography that persists because the shapes are visually apt. mRNA threads through a narrow channel that wraps around the neck between head and body, exposing only about 30 nucleotides of mRNA on the ribosome surface at any time, with a single codon positioned at the decoding center between the head and platform. Universally conserved bases in the 16S rRNA — notably A1492 and A1493 (numbering from E. coli) — flip out of their helix to monitor the geometry of the codon–anticodon minihelix in the A site. If Watson-Crick pairing is correct, these adenines dock snugly against the minor groove; if a mismatch is present, the geometry is distorted and the flipped bases cannot form stabilizing contacts, so the mismatched tRNA is rejected before catalysis can occur. This is a direct, RNA-based proofreading mechanism — no protein enzyme "reads" the code at all.

Large subunit: the catalytic core. The 23S/28S rRNA forms the bulk of the large subunit and creates the peptidyl transferase center (PTC), a pocket built entirely of RNA and located roughly 70–100 Å from the mRNA channel, connected to it via the intersubunit space where the tRNAs' CCA-3′ ends converge. Nearby, a long, narrow exit tunnel — about 80–100 Å long and 10–20 Å wide — channels the growing polypeptide away from the PTC, out through the back of the large subunit, wide enough for an extended chain or even a partially formed alpha helix but too narrow for a folded tertiary structure to form until the chain emerges.

The three tRNA sites, and how a tRNA moves through them. The A site (aminoacyl site) is where incoming aminoacyl-tRNA, delivered as a ternary complex with elongation factor EF-Tu (bacteria) or eEF1A (eukaryotes) and GTP, is first tested against the codon. The P site (peptidyl site) holds the tRNA carrying the growing polypeptide chain. The E site (exit site) transiently holds the deacylated tRNA just before it leaves the ribosome. Each site is actually a composite: it has a piece formed by the small subunit (which contacts the tRNA anticodon and reads the mRNA codon) and a piece formed by the large subunit (which contacts the tRNA acceptor stem and CCA end). A single tRNA molecule, therefore, spans both subunits, sitting in slightly different "small-subunit" and "large-subunit" halves of the A, P, or E position — a fact only resolved once high-resolution crystal structures could be compared directly. The elongation cycle moves each tRNA A→P→E→out in lockstep with mRNA movement, one codon (3 nucleotides) at a time: 1. Aminoacyl-tRNA enters the A site (via EF-Tu·GTP), codon is proofread. 2. Peptide bond forms in the PTC, transferring the growing chain from the P-site tRNA onto the A-site aminoacyl group. 3. Translocation, driven by elongation factor EF-G (bacteria) or eEF2 (eukaryotes) using GTP hydrolysis, ratchets the ribosome exactly one codon along the mRNA, moving the tRNAs from A→P and P→E. 4. The deacylated E-site tRNA dissociates, and the cycle repeats.

The mRNA channel and reading frame maintenance. The mRNA enters the small subunit through an entry channel, is bent roughly 90° as it passes the decoding center, and exits through a separate downstream channel. This channel is narrow enough to enforce single-stranded passage and prevent the ribosome from skipping or slipping frame under normal conditions — mRNA secondary structure (hairpins, pseudoknots) generally must be unwound by the ribosome's intrinsic helicase-like activity or by initiation/elongation factors before it can be threaded through. Because only about one codon's worth of mRNA is exposed in the decoding center at a time, the reading frame set at initiation is mechanically locked in as long as translocation proceeds normally — one reason frameshift mutations have such catastrophic, non-local effects on the resulting protein.

Determining the two-subunit architecture and S values. In the 1950s and 60s, analytical ultracentrifugation — pioneered instrumentally by Theodor Svedberg — allowed researchers to spin cell extracts at enormous speeds (up to ~60,000 rpm) and watch particles sediment as distinct boundaries under a schlieren optical system. Bacterial extracts (Alfred Tissières, James Watson, and colleagues, late 1950s) reliably showed a 70S peak that could be reversibly split, by lowering Mg²⁺ concentration, into 30S and 50S peaks — establishing both that the ribosome is a two-subunit particle and that subunit association is Mg²⁺-dependent, a fact still used today to dissociate ribosomes experimentally.

Proving rRNA structure by comparative sequence analysis. Carl Woese's decades-long project of sequencing 16S rRNA across organisms (starting in the 1970s) was originally aimed at reconstructing the tree of life — and famously revealed the Archaea as a third domain. A byproduct was the discovery that 16S rRNA sequences, though evolving at different rates across lineages, could be folded into an essentially identical secondary structure (stems, loops, pseudoknots) when covariation between paired bases was tracked across hundreds of species. This comparative method — compensatory base changes preserving a helix even as individual bases mutate — gave a highly accurate secondary-structure map of rRNA years before any crystal structure existed, and that map turned out to match the crystallographic structure almost helix for helix.

The decisive experiment: is the peptidyl transferase center RNA or protein? For decades it was assumed a ribosomal protein must catalyze peptide bond formation, since proteins were the only known biological catalysts. Harry Noller and colleagues challenged this directly in 1992: they treated E. coli large subunits with proteases and strong detergents (SDS) to strip away or denature nearly all ribosomal protein, then tested the residual particle for peptidyl transferase activity using a simplified assay (the "fragment reaction," transfer of a formylmethionine analog from a minimal substrate to puromycin). Peptide-bond-forming activity survived this harsh protein-degrading treatment, strongly implicating rRNA, not protein, as the catalytic entity. This was confirmed unambiguously in 2000, when Thomas Steitz, Peter Moore, and colleagues solved the X-ray crystal structure of the Haloarcus marismortui 50S large subunit at 2.4 Å resolution, with a transition-state analog bound in the active site. The structure showed no protein side chain within about 18 Å of the site where the peptide bond forms — every atom lining the catalytic pocket was RNA. This structurally proved the ribosome is a ribozyme: peptide bond formation is catalyzed by folded 23S rRNA, and the nearby ribosomal proteins (notably L27's N-terminal tail) contribute only marginal, largely electrostatic stabilization, not direct chemical catalysis.

Cryo-EM and crystallography of the small subunit and full ribosome. Ada Yonath's decades-long effort (starting in the late 1970s) to grow ribosome crystals — initially considered nearly impossible for such a large, flexible, asymmetric particle — eventually succeeded using ribosomes from extremophile bacteria (Bacillus stearothermophilus, then Deinococcus radiodurans) whose particles were unusually stable and ordered. Venkatraman Ramakrishnan and colleagues then solved the 30S small subunit structure (2000) at high resolution, revealing exactly how the decoding center reads codon-anticodon geometry, including the flipped-out A1492/A1493 adenines. Yonath, Ramakrishnan, and Steitz shared the 2009 Nobel Prize in Chemistry for these structures, which collectively transformed the ribosome from a biochemically inferred black box into an atomically resolved machine.

Example 1 — Sedimentation coefficients don't add. A common student error is expecting 30S + 50S = 80S. Explain why the bacterial ribosome is 70S instead, and predict what would happen to sedimentation behavior if Mg²⁺ is dropped from 10 mM to 1 mM in a bacterial lysate. Reasoning: the Svedberg coefficient depends on the ratio of a particle's sedimentation rate to the applied centrifugal field, which itself depends on mass, density, and shape (specifically, frictional coefficient) — not on mass alone. When two subunits associate, their combined shape becomes more compact and globular than the sum of two separate, more extended particles, so the frictional drag decreases disproportionately. Lower drag partially offsets the added mass, giving a sedimentation coefficient (70S) that is less than the arithmetic sum (80S) of the separate subunits (30S + 50S). Lowering Mg²⁺ from 10 mM to 1 mM destabilizes the electrostatic bridges (including rRNA-rRNA and rRNA-protein contacts) that hold the two subunits together at the interface; the 70S peak on a sucrose gradient would diminish, replaced by separate 30S and 50S peaks — the same experimental logic Tissières and Watson used to first prove ribosomes are built from two dissociable subunits.

Example 2 — Antibiotic selectivity calculation and clinical reasoning. A patient is prescribed erythromycin, a macrolide antibiotic that binds the exit tunnel of the bacterial 50S subunit and blocks nascent chain elongation, for a respiratory infection. A concerned colleague asks: won't this drug also block protein synthesis in the patient's own cells, since human cells also have ribosomes? Reasoning: the drug's selectivity rests on structural divergence between bacterial 70S ribosomes and eukaryotic cytosolic 80S ribosomes, particularly in rRNA sequence and fold near the drug-binding pocket, despite both being built on a broadly conserved architectural plan. Erythromycin binds a specific nucleotide pocket in the bacterial 23S rRNA exit tunnel wall that differs enough in sequence and structure from the human 28S rRNA equivalent that the drug binds bacterial ribosomes with far higher affinity than human cytosolic ribosomes. However, human mitochondrial ribosomes, being evolutionary descendants of an ancient bacterial endosymbiont, retain enough structural similarity to the bacterial exit tunnel that some macrolides can partially inhibit mitochondrial translation at high doses — a mechanistic basis for rare macrolide side effects (e.g., mitochondrial toxicity) in some patients, and a live reminder that "bacteria-specific" drug targets are matters of degree, rooted directly in Endosymbiotic Theory, not absolute categorical difference.

Ada Yonath spent nearly two decades pursuing a goal that many crystallographers considered essentially unattainable: growing ordered, diffracting crystals of an intact ribosomal subunit. Ribosomes are enormous by crystallography standards, conformationally flexible, and studded with a shifting halo of loosely bound waters and ions — properties that make orderly crystal packing extraordinarily difficult. Yonath's insight was to seek ribosomes from organisms adapted to biochemical extremes, reasoning that unusually stable ribosomes from heat- or radiation-tolerant bacteria might crystallize more readily than those from standard lab strains. Her persistence through the 1980s, when many crystals diffracted poorly or not at all, eventually yielded diffraction-quality crystals, and by the late 1990s and 2000s her group and others achieved atomic-resolution structures of the small and large subunits.

Ribosome structure is a live target in medicine: a large fraction of clinically used antibiotics — macrolides, aminoglycosides, tetracyclines, oxazolidinones, and others — work precisely because bacterial 70S ribosomes are structurally distinct enough from human 80S cytosolic ribosomes to be selectively targeted, even though both share a common evolutionary and mechanistic core. Structural knowledge of exactly where these drugs bind (the exit tunnel, the decoding center, the A site) has enabled rational design of next-generation antibiotics aimed at overcoming resistance mutations that alter rRNA at the drug-binding pocket. In cancer and genetic disease, "ribosomopathies" — conditions like Diamond-Blackfan anemia — arise from mutations in ribosomal proteins or rRNA processing factors, producing tissue-specific defects that structural biology helps explain by pinpointing which assembly step or subunit region is disrupted. In biotechnology, engineered or minimal ribosomes are used in cell-free protein synthesis systems for on-demand vaccine and biologic-drug production, and orthogonal ribosomes (re-engineered to read expanded genetic codes) are a core tool for incorporating unnatural amino acids into proteins for research and industrial use. In evolutionary biology, the near-universal conservation of rRNA core structure across all three domains of life makes ribosomal RNA sequence — especially 16S/18S rRNA — the standard molecular clock for reconstructing the Tree of Life and identifying microbial species in environmental and clinical samples.

Ask the tutor: How does the ribosome physically choose the correct start codon during translation initiation, and how does this differ between bacteria and eukaryotes?